Initial research are creating significant attention surrounding the medication, a promising dual agonist targeting gut peptides and glucose-dependent insulinotropic polypeptide. Compared to existing obesity medications , this treatment seems to offer greater reductions in abdominal circumference and boost glucose health in early results. Although